The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Defining Cognitive Phenotypes of Parkinson’s Disease, 2011Neurochemical Correlates of Cognitive Phenotypes in PD
Objective/Rationale:
Parkinson’s disease causes neurodegeneration in multiple subcortical nuclei, including substantia nigra, locus coeruleus, dorsal raphe nucleus, and nucleus basalis. Each of these... -
Target Validation, 2011TGF-beta Signaling as Novel Therapeutic Treatment for Parkinson's Disease
Objective/Rationale:
Finding ways to protect dopaminergic neurons from degeneration could provide new therapies for Parkinson’s disease (PD). Transforming growth factor betas (TGF-betas) are essential... -
Therapeutics Development Initiative, 2011Development of Posiphen to Treat Parkinson's Disease
Objective/Rationale:
Posiphen is a small molecule drug that inhibits expression of alpha-synuclein, a protein involved in Parkinson's disease (PD) pathogenesis. We propose studies in a pre-clinical... -
Target Validation, 2011Validation of Skp1 as a New Target for PD Therapy
Objective/Rationale:
Multiple evidence supports the notion that a malfunction of the ubiquitin-proteasome system and autophagy plays a crucial role in protein misfolding and aggregation in Parkinson... -
LRRK2, 2011DAT Imaging in Unaffected LRRK2 Gene Positive Subjects in a Chinese Community Cohort
Objective/Rationale:
While most PD is not associated with a specific genetic cause, the genetic mutation affecting the LRRK2 gene has been identified as a cause of PD in selected families and... -
MJFF Research Grant, 2011Laboratory Phenotyping of Parkinson Disease Subjects Using a Multiplex Approach
Promising Outcomes of Original Grant:
With the original funded grant we have successfully optimized the measurement of total alpha-synuclein and DJ-1 in cerebrospinal fluid as promising markers for...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.